Posted by Michael Wonder on 09 Nov 2017
Decision to fund zoster vaccine
9 November 2017 - PHARMAC is pleased to announce the approval of an agreement with Merck Sharpe & Dohme to fund the zoster vaccine (Zostavax) for the prevention of shingles (herpes zoster) from 1 April 2018.
Zoster vaccine will be listed in Section I (National Immunisation Schedule) and in Part II of Section H of the Pharmaceutical Schedule for people aged 65 years, with a 2-year catch up programme for people aged between 66 and 80 years inclusive.
